bioRxivImmunologyPreprint
T cell engagers convert acute tumor killing into endogenous vaccination
Mathilde M. Lecuit, Béatrice CorreiD, Zacarias GarciaiD, Fabrice Lemaı̂treiD, Amaury VaysseiD, Ruby AlonsoiD, Christel GoudotiD, Baptiste Arnaud, L FeldmanniD, Carolina Moraes Cabe, Valérie Seffer, Pierre GuermonpreziD, Capucine L. GrandjeaniD, Marion V. GuériniD, Philippe BoussoiD
Abstract
T cell engagers (TCEs) redirect T cells to kill tumors by cross-linking CD3{varepsilon} to a tumor antigen, independently of T cell receptor specificity. Some patients achieve remissions that persist long after drug clearance, but whether TCEs can couple acute cytotoxicity to the generation of lasting adaptive immunity remains unknown. Here, using an immunocompetent mouse model for clinical-grade human TCEs, we show that TCE-mediated killing initiates an endogenous vaccination cascade. Intravital two-photon imaging reveals a perforin-dependent cytotoxic wave that peaks within 24 hours, then subsides despite massive T cell accumulation. Single-cell transcriptomics and adoptive transfers demonstrate that memory CD8 T cells, the principal effector reservoir in mouse and human, transit through a progenitor-like state before differentiating into cytotoxic effectors with recall competence. Crucially, tumor lysis fuels cross-priming of tumor-specific CD8 T cells by XCR1 type 1 conventional dendritic cells, a cDC1-dependent step essential for durable tumor control and protective memory upon rechallenge.
- organism: mouse
- assay: spatial transcriptomics
- assay: bulk RNA-seq
- research focus: cell-cell communication
- research focus: trajectory inference
- research focus: differential expression
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Successful dendritic cell vaccines require lasting in-situ TNF α secretion to license antitumor CD8 + T cell cytotoxicity
Nadine Santana-Magal, Aseel Khateeb, … Yaron Carmi·bioRxiv·Apr 8, 2026
- Pre-existing intratumoral CD8 T cells substantially contribute to control tumors following therapeutic anti-CD40 and polyI:C based vaccination
A. Stevens, T. N. Bullock·bioRxiv·Aug 31, 2020
- Targeting human γδ T cells as a potent and safe alternative to pan-T cells bispecific cell engagers
- Lymph node-targeted vaccine boosting of TCR-T cell therapy enhances anti-tumor 1 function and eradicates solid tumors
D. J. Drakes, A. M. Abbas, … P. C. DeMuth·bioRxiv·May 5, 2022
- T cell engagers control solid tumors through clonal replacement and IL2-driven effector differentiation of CD8 T-cells
Matthias Obenaus, Clara L. Poupault, … K. Christopher García·bioRxiv·Jan 27, 2026
- Long-term efficacy of adoptive cell therapy is determined by host CD8+ T cells and undermined by lymphodepleting preconditioning
Diego A. Figueroa, Juan Pablo Vega, … Álvaro Lladser·bioRxiv·May 16, 2024